# Citations for Research Query

**Query:** # Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Ovarian High-Grade Serous Carcinoma
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** restored_hrr_reversion_resistance_model
- **Hypothesis Label:** Restored HRR via BRCA Reversion Resistance Model
- **Status in KB:** CANONICAL

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: restored_hrr_reversion_resistance_model
hypothesis_label: Restored HRR via BRCA Reversion Resistance Model
status: CANONICAL
description: Resistant HGSOC subclones acquire BRCA1, BRCA2, or PALB2 reversion mutations that restore
  HRR function and abolish the synthetic-lethal relationship. Reversion alleles are detectable in ctDNA
  at progression and are the principal documented mechanism of clinical PARP-inhibitor resistance.
evidence:
- reference: PMID:36243543
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: No baseline BRCA reversion mutations were observed in 100 BRCA+ patients. NGS identified somatic
    BRCA reversion mutations in 39% (39/100) of patients after progression.
  explanation: TRITON2 establishes acquired BRCA reversion mutations in ~39% of progression specimens
    as the principal acquired-resistance event.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.

**Provider:** asta
**Generated:** 2026-05-26T23:12:30.269417

1. Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al. (2018). Gathering Evidence of Mechanisms. https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
2. J. Skogen, S. Øverland (2012). The fetal origins of adult disease: a narrative review of the epidemiological literature. JRSM Short Reports. https://www.semanticscholar.org/paper/b665dc20a1f7355f7c82e370d1e1fa3a0e2a7fce
3. Lang Qin, Z. Gan, Xu Cao, Pengcheng Jiang, Yankai Jiang et al. (2025). RareAgent: Self-Evolving Reasoning for Drug Repurposing in Rare Diseases. ArXiv. https://www.semanticscholar.org/paper/ad0dc7cd9de3e46fb22cc025706d54dfe58331a0
4. G. Saed, R. T. Morris, N. Fletcher (2018). New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress. Ovarian Cancer - From Pathogenesis to Treatment. https://www.semanticscholar.org/paper/6c74938095716cbd46a218acde0b4b89bd78f7ae
5. F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al. (2018). A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. NPJ Systems Biology and Applications. https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
6. C. Tung, S. Mok, Y. Tsang, Z. Zu, Huijuan Song et al. (2009). PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. https://www.semanticscholar.org/paper/120fdba92f33c126e0e86008300cb927c4350a14
7. T. Motohara, K. Masuda, M. Morotti, Yiyan Zheng, Salma El-Sahhar et al. (2018). An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene. https://www.semanticscholar.org/paper/94e8742c8e77f59c6a2648bfdf0d8a9c9c928d7b
8. A. Oulas, Kyriaki Savva, Nestoras Karathanasis, George M. Spyrou (2023). Ranking of cell clusters in a single-cell RNA-sequencing analysis framework using prior knowledge. PLOS Computational Biology. https://www.semanticscholar.org/paper/efaf940a9b0405a5405ebf033673f32b3a1268df
9. Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin et al. (2025). DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research. ArXiv. https://www.semanticscholar.org/paper/f06a59cb27b36766098ecb235c9ada048e145ed0
10. G. Nohynek, C. Borgert, D. Dietrich, K. Rozman (2013). Endocrine disruption: fact or urban legend?. Toxicology letters. https://www.semanticscholar.org/paper/a84380ac3115ab9bed7424722a2049419d87afa3
11. Christophe Gerard Lambert, L. Black (2012). Learning from our GWAS mistakes: from experimental design to scientific method. Biostatistics (Oxford, England). https://www.semanticscholar.org/paper/7c92a4bffd527e9275e5dbc57e2037bc07fa93f9
12. Chun-Chi Liu, Y. Tseng, Wenyuan Li, Chia-Yu Wu, I. Mayzus et al. (2014). DiseaseConnect: a comprehensive web server for mechanism-based disease–disease connections. Nucleic Acids Research. https://www.semanticscholar.org/paper/164eec8e3e9af7dd3b1182e46be7577b90d44e1b
13. Michael Wilde (2021). Mechanistic reasoning and the problem of masking. Synthese. https://www.semanticscholar.org/paper/2ca9800e6991ee25dc9a167da8d1f88c3b4f3d94
14. Christopher G. Smith (2017). A Resident’s Perspective of Ovarian Cancer. Diagnostics. https://www.semanticscholar.org/paper/e7187ce9b848d3233d797ed025fd8984fdc4cd36
15. Ali E. Ghareeb, Benjamin Chang, L. Mitchener, Angela Yiu, Caralyn J. Szostkiewicz et al. (2025). Robin: A multi-agent system for automating scientific discovery. ArXiv. https://www.semanticscholar.org/paper/799017d2818108e91392c541579cbe9d2cc38e35
16. Jack Freeman, R. Millikin, Leo Xu, Ishaan Sharma, Bethany Moore et al. (2025). SKiM-GPT: combining biomedical literature-based discovery with large language model hypothesis evaluation. BMC Bioinformatics. https://www.semanticscholar.org/paper/ce7a6900a181708dba6ed2bf612d06b0be1d20b1
17. S. Satapathy, Chanchal Kumar, R. Singh (2019). MicroRNAs as Key Regulators of Ovarian Cancers. Cell Medicine. https://www.semanticscholar.org/paper/15e1b4b2236e99d2745e80baf8a98f3b45e8f432
18. T. Edwards, Stephen D. Turner, E. Torstenson, S. Dudek, E. Martin et al. (2010). A General Framework for Formal Tests of Interaction after Exhaustive Search Methods with Applications to MDR and MDR-PDT. PLoS ONE. https://www.semanticscholar.org/paper/4de432bf6a4637abd951bbda473ccc57ca98128c
